Business context and reporting period
Filing identity: The request names Imunon, Inc., but the supplied Form 10-Q is for Celsion Corporation (now associated with the Imunon name). It covers the quarter and nine months ended September 30, 2015; financial statements are unaudited.
Celsion was a clinical-stage oncology drug developer. Its lead candidate, ThermoDox, was in Phase III development for primary liver cancer and Phase II development for recurrent chest-wall breast cancer. The portfolio also included GEN-1 and the TheraPlas and TheraSilence platforms acquired from EGEN.
Financial performance and condition
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $125,000 | $375,000 | $375,000 |
| Operating expenses | $4.37 million | $6.79 million | $16.27 million | $18.66 million |
| Operating loss | $4.24 million | $6.67 million | $15.90 million | $18.28 million |
| Net loss | $4.27 million | $6.94 million | $16.95 million | $19.04 million |
| Basic and diluted loss per share | $0.19 | $0.40 | $0.79 | $1.12 |
- Revenue was licensing-fee amortization; the filing reports no meaningful product sales or gross margin. The business remained loss-making and dependent on financing.
- R&D was $2.88 million in Q3 and $10.96 million year to date. Q3 R&D declined 38% year over year, largely reflecting lower clinical research costs and a $0.8 million reduction in a cooperative research agreement liability. Year-to-date R&D increased 2.5%.
- G&A declined 27% in Q3 and 22% year to date, primarily due to lower personnel and insurance costs. Acquisition costs were nil in 2015 versus $1.19 million year to date in 2014.
- At September 30, cash, cash equivalents, short-term investments and related interest receivable totaled approximately $24.4 million, down from $37.1 million at December 31, 2014. Current assets were $24.8 million; current liabilities were $8.4 million; working capital was $16.4 million.
- Operating cash use was $16.93 million for the first nine months, compared with $14.84 million in 2014. Investing activities provided $7.36 million, mainly reflecting net maturities and sales of securities; financing provided $4.46 million, including $7.16 million net equity proceeds less $2.70 million in debt principal payments.
- Notes payable totaled about $7.32 million on the balance sheet, including $3.98 million current and $3.34 million non-current. The Hercules debt carried an 11.25% annual interest rate; scheduled principal payments before debt discounts were $7.30 million. Management reported compliance with debt covenants.
- Accumulated deficit was $212.5 million. Stockholders’ equity was $25.1 million. The company had 23.03 million common shares outstanding at September 30 and reported 23.24 million as of November 4, 2015.
Material changes versus the prior comparable period
- Q3 net loss narrowed by $2.67 million year over year; nine-month net loss narrowed by $2.09 million. Lower operating expenses were partly offset by higher year-to-date interest expense and other expense.
- Cash and short-term investments fell approximately $12.7 million from December 31, 2014, while working capital declined from $27.4 million to $16.4 million.
- The June 2015 registered direct offering issued 3.0 million shares at $2.675 per share for $8.0 million gross proceeds, alongside five-year warrants for up to 1.95 million shares at $2.60 per share.
- The common-stock warrant liability was reduced to zero in Q2 after an exercise-price adjustment provision expired; $336,254 was reclassified to equity. The EGEN earn-out liability was $13.62 million at quarter end, with a $282,950 non-cash Q3 gain from revaluation.
Outlook, management commentary, risks and unusual items
- Management said the $24.4 million of cash and investments was expected to fund operations into the first half of 2017. The filing provides no revenue or earnings guidance. Management cautioned that future capital needs depend on clinical, regulatory and other uncertain factors and that additional capital may be required.
- The Phase III HEAT trial of ThermoDox with radiofrequency ablation failed its primary progression-free-survival endpoint in 2013. Management cited a post-hoc subgroup analysis showing a 58% improvement in overall survival for patients receiving optimized ablation; this analysis was not the failed trial’s primary endpoint and is not confirmatory evidence.
- The Phase III OPTIMA study was underway, designed to enroll up to 550 patients and evaluate ThermoDox with standardized radiofrequency ablation. The Phase II DIGNITY study reported interim local response in 9 of 13 evaluable patients, including five complete and four partial responses; the company planned to present final results in December 2015.
- The first patient was enrolled in the GEN-1 Phase I Ovation ovarian-cancer study on September 30, 2015. The company also planned a separate GEN-1 combination trial in platinum-resistant ovarian cancer, with enrollment expected in the first half of 2016.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, reliance on third-party trial and manufacturing providers, ongoing losses and potential dilution from future financing. The company had no off-balance-sheet financing arrangements and reported no legal proceedings.
- The EGEN acquisition included up to $30.4 million of contingent milestone payments, payable in cash, shares or a combination at Celsion’s option. Management concluded that acquired in-process R&D and goodwill were not more likely than not impaired as of September 30, 2015; both valuations involve significant assumptions.
- Disclosure controls were assessed as effective at the reasonable-assurance level, and the filing reported no material change in internal control over financial reporting during the period.
Important facts for investors to verify
- Confirm the issuer and security intended: the supplied filing is Celsion Corporation’s 2015 Form 10-Q, not a filing under the requested Imunon, Inc. name.
- Review the OPTIMA trial’s enrollment, execution, and outcomes, and distinguish prospective trial results from the post-hoc HEAT subgroup analysis.
- Assess the cash runway against actual operating cash burn, scheduled debt payments, clinical spending, and access to additional financing.
- Evaluate dilution from outstanding warrants, options, equity plans, future offerings, and potential EGEN milestone payments.
- Check the assumptions and potential cash or share consequences of the $13.62 million EGEN earn-out liability and the impairment assessments for acquired assets.